Long-term efficacy data shows MDMA is effective for treating PTSD

The Multidisciplinary Association for Psychedelic Studies (MAPS) is producing the first-in-class innovator drug midomafetamine (MDMA) as therapy for chronic and delayed-onset post-traumatic stress disorder (PTSD), currently in Phase III development in the US and Europe. Following positive Phase II trial data confirming that midoafetamine resulted in a significant reduction in PTSD symptoms, the FDA granted it a Breakthrough Therapy Designation in 2017.

Further results proceed to prove MDMA’s effectiveness in treating PTSD. Read more here.